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Abstract
Background and Aims: Connexins and their cell membrane channels contribute to the control of cell proliferation and
compartmental functions in breast glands and their deregulation is linked to breast carcinogenesis. Our aim was to correlate
connexin expression with tumor progression and prognosis in primary breast cancers.
Materials and Methods: Meta-analysis of connexin isotype expression data of 1809 and 1899 breast cancers from the
Affymetrix and Illumina array platforms, respectively, was performed. Expressed connexins were also monitored at the
protein level in tissue microarrays of 127 patients equally representing all tumor grades, using immunofluorescence and
multilayer, multichannel digital microscopy. Prognostic correlations were plotted in Kaplan-Meier curves and tested using
the log-rank test and cox-regression analysis in univariate and multivariate models.
Results: The expression of GJA1/Cx43, GJA3/Cx46 and GJB2/Cx26 and, for the first time, GJA6/Cx30 and GJB1/Cx32 was
revealed both in normal human mammary glands and breast carcinomas. Within their subfamilies these connexins can form
homo- and heterocellular epithelial channels. In cancer, the array datasets cross-validated each other’s prognostic results. In
line with the significant correlations found at mRNA level, elevated Cx43 protein levels were linked with significantly
improved breast cancer outcome, offering Cx43 protein detection as an independent prognostic marker stronger than
vascular invasion or necrosis. As a contrary, elevated Cx30 mRNA and protein levels were associated with a reduced disease
outcome offering Cx30 protein detection as an independent prognostic marker outperforming mitotic index and necrosis.
Elevated versus low Cx43 protein levels allowed the stratification of grade 2 tumors into good and poor relapse free survival
subgroups, respectively. Also, elevated versus low Cx30 levels stratified grade 3 patients into poor and good overall survival
subgroups, respectively.
Conclusion: Differential expression of Cx43 and Cx30 may serve as potential positive and negative prognostic markers,
respectively, for a clinically relevant stratification of breast cancers.
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Introduction
Breast cancer is one of the most fatal malignancies of women in
the economically developed countries [1]. In addition to clinico-
pathological factors, molecular techniques allow clinically relevant
subtyping of breast cancers by testing for biomarkers of tumor
prognosis and response to therapy (prediction) [2,3]. However,
despite accurate testing, only ,50% of the selected cases respond
e.g. to anti-Her2 immunotherapy [4]. Therefore, further stratifi-
cation within breast cancer subtypes is needed to assist in selecting
more personalized treatment options and revealing the back-
ground of therapy resistance.
Homeostasis in breast tissue requires regulated direct cell-cell
interactions. Abnormal expression of adherent (E-cadherin) and
tight junction proteins (claudins) in mammary glands has been
demonstrated to contribute to breast cancer development and to
assist in clinical subtyping [5,6]. Recently, we have found that
monitoring connexin (Cx) proteins Cx26 and Cx46 in neoadjuvant
treated breast cancer allowed refinement of intermediate prog-
nostic subgroups of residual tumor classifications [7]. Connexins
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and their cell membrane channels play essential roles in the
control of cell proliferation, differentiation and apoptosis and their
deregulation can contribute to carcinogenesis including breast
cancers [8,9]. However, no comprehensive study correlating
connexin mRNA and protein levels with breast cancer progression
and prognosis have been published.
Six of the tetraspan transmembrane connexins form hemi-
channels which can align for gap junctions in adjacent cells
allowing the orderly transport of,,1,8 kDa regulatory molecules
between coupled cells including ions, metabolites (nucleotides,
linear oligopeptides), second messengers (c-AMP, IP3 and Ca
2+)
and morphogenes [10,11]. Connexins may also function as
hemichannels or through intracellular protein-protein interactions
with oncogene products such as Src, signaling protein kinases and
cytoskeletal elements [12–14]. More than one of the 21 cloned
connexin isotypes are expressed in most human cell types [15] and
their importance is reflected by their ubiquitous presence and large
density in all solid tissues, early emergence during embryogenesis
and high evolutionary conservation throughout vertebrates [10].
Principal connexin functions are related to the maintenance of cell
homeostasis and integration of compartmental activities within cell
networks [16].
Connexins and gap junctions have long been implicated in
tumor suppression [17]. Though connexins can be upregulated in
dysplasia or early cancer [18], their expression and functions are
usually reduced in malignant tumors [19] and can be aborted in
advanced cancers [20]. However, recent observations suggest a
context dependent regulation of connexins in cancer with
occasional stage dependent up-regulation [13]. Furthermore,
connexin isotypes not found in the normal tissue may also emerge
in the related cancer [21].
Available data on connexin expression in normal breast and
breast cancer are controversial. Limitations of large scale screening
of connexins are explained by scarce antibodies detecting their
isotypes in archived tissues and difficulties of resolving the small (,
1 mm) connexin plaques in ,5 mm thick sections. So far, Cx43
and Cx26 have been detected to contribute to human [22–25] and
Cx30 and Cx32 to mouse mammary gland development and
lactation [26]. In primary breast cancers Cx43 and Cx26 have
been suggested as tumor suppressors [27,28]. However, increased
Cx43, Cx26 and Cx32 protein levels have also been found in
lymph node metastases compared to primary breast cancers
[29,30] but without correlation to disease prognosis [8]. Recently,
Cx46 has also been implicated in the adaptation of breast cancer
cells to hypoxia [31]. Furthermore, heterocellular communication
between breast carcinoma cells and vascular endothelia has been
confirmed during metastatic tumor invasion [32,33].
Here, we tested publically available mRNA expression array
databases and tissue microarray (TMA) series of breast cancers for
connexin isotype expression. Based on mRNA expression data, a
comprehensive screening for five connexin isotypes, GJA1/Cx43,
GJA3/Cx46, GJB2/Cx26, GJA6/Cx30 and GJB1/Cx32 was
performed at the protein level in normal pre-menopausal breast
glands and in a cohort of cancers representing all grades and
major breast cancer subtypes. Differential connexin expression
showed significant correlations with tumor progression and disease
outcome for potential utilization in breast cancer diagnostics and
treatment design.
Materials and Methods
In silico connexin mRNA expression data analysis in
breast cancer
An in silico analysis was carried out using the web-based
Kaplan-Meier Plotter (http://kmplot.com) [34] utilizing publicly
available gene expression data of HGU133A and HGU133+2
microarrays (Affymetrix, Santa Clara, CA) and survival informa-
tion of 1809 patients from gene expression omnibus (GEO)
(Table 1). Expression data were available for Cx32, Cx43 and
Cx46. High and low expression groups were separated along the
median connexin expression for each isotype (Fig. S1) and
investigated in context with relapse free survival (RFS), overall
survival (OS) and distant metastasis free survival (DMFS). Data for
Cx26 and Cx30 mRNA expression of 1899 breast cancers,
published in the METABRIC project using the Illumina HT-12
v3 platform (San Diego, CA) were downloaded from the European
Genome-Phenome Archive [35]. Overlapping data on Cx32,
Cx43 and Cx46 were used to verify the Affymetrix array results.
Expression data were filtered by ER and HER2 status, major
subtypes, lymph node involvement and/or tumor grade. Patient
datasets were also grouped according to systematically untreated
cases, endocrine-treated ER positive cases and a patient cohort
similar to SEER (Surveillance Epidemiology and End Results)
prevalence. The clinicopathological features of tumor samples
tested for connexin mRNA expression are summarized in
Table 1.
Breast cancer samples tested for protein expression
This study was approved (#85/2007) by the Institutional
Review Board (IKEB) of Semmelweis University (Budapest,
Hungary). The Regional Committee of Science and Research
Ethics waived the need for individual patient consent on archived
tissues available for primary diagnostics for further testing of
potential biomarkers.
Formalin-fixed, paraffin-embedded (FFPE) tissue samples of 127
primary breast cancers collected between 1999 and 2002 at Buda
MAV Hospital, Budapest, Hungary were studied (Table 1). This
study was approved (#85/2007) by the Institutional Review Board
(IKEB) of Semmelweis University (Budapest, Hungary). Patients
were subjected to partial or total mastectomy optionally accom-
panied by axillary block dissection. Fifty patients (39.4%)
underwent operation without any supplementary treatment, 16
patients (12.6%) received irradiation only, 12 patients (9.4%)
received taxane- or antracycline-based chemotherapy only, 40
patients (31.5%) were subjected to trimodality treatment and in 9
patients (7.1%) there was no treatment information available.
Breast carcinomas were immunophenotypically classified into 4
subgroups. Luminal A phenotype (estrogen/ER -and progester-
one/PR receptor positive, epidermal growth factor receptor 2/
HER2 negative tumors with Ki67 expression in ,20% of tumor
cells) was detected in 70 cases, luminal B subtype (ER/PR and
HER2 double positive tumors; or ER/PR positive and HER2
negative tumors with .20% Ki67 positive tumor cells) was
established in 19 cases, triple negative subtype (ER/PR negative
and FISH confirmed HER2 negative tumors) was found in 21
cases and HER2 positive subtype (ER and PR negative and
immunohistochemically HER2 3+ or 2+ cases where gene
amplification was confirmed by FISH) was detected in 15 cases.
Immunophenotype was not available for two patients. At least
duplicate cores of 2 mm diameter were collected from the
archived tissue blocks into TMAs using a manual array builder
(Histopathology Ltd., Pecs, Hungary) including 41 grade1, 41
grade2 and 44 grade3 tumors. Normal mammary glands of 3 pre-
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menopausal women were also examined for connexin expression.
The clinicopathological features of tumor samples tested are
shown in Table 1.
Immunofluorescence detection of connexins and cell
proliferation
To resolve the small size (frequently ,1 mm) connexin plaques
through the 4 mm thick sections in a large number of samples
without fading a sensitive immunofluorescence detection was set
up combined with multilayer (3–5 layers) whole slide digitalization
for permanent archives using Pannoramic Scan (3DHISTECH).
TMA slides were routinely de-waxed in xylene and rehydrated
through graded ethanol series. Antigen unmasking was done in a
buffer containing 0.1 M Tris and 0.01 M EDTA (pH 9.0) using an
electric pressure cooker (Avair, Biofa, Veszprem, Hungary) for
20 min at ,105uC. Slides were then briefly digested using 0.25%
Gibco trypsin phenol red (1:50, Life Technologies, Carlsbad, CA,
Ref: 25050-014) for 10 sec. After protein blocking in 1% BSA-
TBS (0.1 M Tris-buffered saline, pH7.4) for 20 min, the slides
were incubated overnight with antibodies, validated for isotype
size in western blots, recognizing human or rat connexin
sequences including mouse anti-Cx26 (1:500, clone: CX-1E8,
Invitrogen/2Life Technologies, Eugene, OR), and rabbit anti-
Cx30 (1:75, code: HPA014846, Sigma-Aldrich, St Luis, MO),
-Cx32 (1:30, code: HPA010663, Sigma-Aldrich), -Cx43 (1:100,
code: #3512, Cell Signaling, Beverly, MA) and -Cx46 (1:100,
code: SAB1300557, Sigma-Aldrich). Mammal connexin-specific
antibodies show high degree of cross-reactivity with the relevant
human connexins [15]. The proliferation marker Ki67 protein was
also simultaneously detected using the mouse anti-human Mib1
clone (1:2 ready-to-use, code: IR626, Dako, Glostrup, Denmark),
or the rabbit SP6 clone (Thermo-LabVision, Fremount, CA)
combined with the mouse anti-Cx26 antibody. For double antigen
detection slides were incubated with a mixture of Alexa Fluor 564
goat anti-rabbit IgG (red, code: A11035) and Alexa Fluor 488 goat
anti-mouse IgG (green, code: A11001) diluted in 1:200, for
90 min. Cell nuclei were stained using Hoescht (blue, code:
B2883) in 1:1000 for 90 sec (all fluorochrome labeled reagents
were from Invitrogen-life Technologies). All incubations were
done in humidity chambers at room temperature and slides were
washed between the steps using 0.1 M TBS (Tris-buffered saline)
pH 7.4 for 265 min.
Evaluation of connexins and cell proliferation in breast
cancer
Connexins are known to form transmembrane hemichannels
and gap junctions and can directly interact with regulatory
proteins within cells resulting in particulate cell membrane and
cytoplasmic signals [13]. Both localizations were taken into
account at analysis. Connexin expression was tested in digital
slides using Pannoramic Viewer (version 1.15) software on a 4-
scale scoring system considering the frequency of positive tumor
cells. Score 0: ,5% positive cells; +1:5–20% positive cells; +2:21–
50% positive cells; +3: .50%.
The Ki67 immunoreaction was evaluated using a linear 10-scale
scoring system based also on the positive tumor cell fractions
(Score 0:0, 1:0–1%, 2:1–5%, 3:6–10%, 4:11–15%, 5:16–20%,
6:21–33%, 7:34–50%, 8:51–66%, 9:67–80%, 10:81–100%).
Table 1. Primary breast cancers tested for connexin expression using in silico microarray datasets for mRNA or tissue microarray
sections for protein analysis.
In silico datasets
Cohort Affymetrix Illumina TMA samples
Patients (n) 1809 1988 127
Age (years 6 SD) 57613 61.8 (median) 59612
Follow-up time (months 6 SD) 123682 86.4 (median) 101640
Relapse/Death event (n %) 690 (38.1%) 643 (32.3%) 42 (33.1%)
Grade 1 198 (10.9%) 170 (8.6%) 41 (32.3%)
Grade 2 534 (29.5%) 775 (39%) 41 (32.3%)
Grade 3 312 (17.2%) 954 (48%) 44 (34.6%)
Data not provided 745 (41.2%) 89 (4,4%) 1 (0.8%)
IDC 0 0 88 (69.3%)
ILC 0 0 13 (10.2%)
Other 0 0 14 (11.0%)
Data not provided 1809 1988 12 (9.4%)
ER positive 968 (53.5%) 1517 (76.3%) 89 (70.1%)
Luminal A 969 (53.6%) 825 (41.5%) 70 (56%)
Luminal B 536 (29.6%) 668 (33.6%) 19 (15.2%)
ER negative 578 (31.9%) 471 (23.7%) 36 (28:3%)
HER2 positive 295 (16.3%) 242 (12.1%) 15 (12%)
TNBC 230 (12.7%) 331 (16.7%) 21 (16.8%)
Unknown 0 0 2 (1.6%)
TMA: tissue microarray; SD: standard deviation; IDC: invasive ductal carcinoma.
ILC: invasive lobular carcinoma; ER: estrogen receptor; TNBC: triple negative basal cell type.
Note: Technically unsatisfactory samples were left out.
doi:10.1371/journal.pone.0112541.t001
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Statistical analysis
The gene chip mRNA expression results were analyzed within
the R statistical environment (R version 2.10.1; R Foundation for
Statistical Computing, Vienna, Austria) as described previously
[36]. Results were shown in Kaplan-Meier plots including the
hazard ratios and P of the log-rank test. For statistical testing of
protein expression scores gained in TMA sections of breast cancer
samples the SPSS 15.0 software was used (SPSS Inc., Chicago, IL).
Connexin isotype expression was correlated both with protein
levels in normal mammary glands and with clinicopathological
features including grade, hormone receptor status (HR), presence
of necrosis and invasion, Nottingham Prognostic index (NPI) and
mitotic index (MI) using the Spearman-rank test. Prognostic
relevance of connexin isotype expression estimating overall
survival (OS), disease-free survival (DFS) and distant metastasis
free survival (DMFS) were evaluated with the log-rank test. Cox
proportional hazard regression was used to quantify the influence
of variables in univariate analysis and to assess those in
multivariate models which were significantly associated with
survival but without direct significant pairwise correlations when
using the Spearman’s rank test. Hazard ratios (HR) were given
with 95% confidence intervals (95% CI). P values of ,0.05 were
considered statistically significant in all tests.
Results
In silico analysis of connexin mRNA expression in breast
cancer
Affymetrix dataset. Correlates between connexin mRNA
expression and disease prognosis are summarized in Table 2 and
some are highlighted in Kaplan-Meier plots. Significantly better
RFS was linked with tumors showing: elevated (.median) Cx32
mRNA levels in the whole patient cohort; elevated Cx43 mRNA
levels in a tumor group similar to SEER prevalence (Fig. 1a), in
the ER positive tumors, in the Luminal A group, in the ER and
lymph node positive tumors (Fig. 1b) and in ER positive
endocrine treated tumors (Fig. 1c). Elevated Cx43 mRNA
expression was associated with shorter RFS only in the ER
negative group (Fig. 1d). Increased Cx46 expression was also
predictive for longer RFS in the whole patient cohort (Fig. 1e)
and in the ER and lymph node double positive grade 3 patients
(Fig. 1f). Elevated Cx43 mRNA levels were also associated with
significantly longer DMFS in the whole patient cohort, in the
lymph node negative patients, in the ER positive endocrine-
treated patients (Fig. 1 g) and in grade 2 cancers (Fig. 1 h).
Again, in ER negative patients Cx43 expression showed an inverse
correlation with prognosis (OS) (Fig. 1i).
Illumina dataset. Significant prognostic correlations of
Cx26 and Cx30 mRNA expression, data not available in the
Affymetrix set, and of Cx32, Cx43 and Cx46 are summarized in
Table 2. Except for a significant inverse correlation with OS in
luminal B tumors, Cx26 mRNA expression did not show
significant link with breast cancer prognosis. Cx30 mRNA levels,
however, were inversely correlated with OS in the whole cohort, in
the ER positive patients, both in the Luminal A and Luminal B
patient subgroups (Fig. 2a) and in the ER positive endocrine
therapy treated patients (Fig. 2b). As a contrary, elevated Cx30
mRNA levels were associated with a strong tendency of longer OS
in the ER negative group including the HER2 positive and the
triple negative (Fig. 1c) patient groups.
Prognostic OS data of the Illumina platform on Cx43, Cx46
and Cx32 expression correlated well with DFS figures of the
Affymetrix platform. Accordingly, elevated Cx43 levels showed a
significant positive association with OS in the whole patient cohort
(Fig. 2d), in the ER positive group, in the luminal A tumors and
in the ER positive endocrine therapy treated patients (Fig. 2e).
However, elevated Cx43 levels showed an inverse statistical trend
with OS in the ER negative cases (Fig. 2f) and in the triple
negative cases. Elevated Cx46 expression was associated with
improved OS in the whole patient cohort (Fig. 2 g), in the
Luminal A group, in the ER negative patients (Fig. 2 h), in the
HER2 positive patients (Fig. 2i) and in the chemotherapy treated
patients. Increased Cx32 expression was also linked with favorable
OS in the whole cohort, in the ER positive patients, mainly in the
Luminal B subgroup and in the ER positive endocrine therapy
treated patients.
Expression of connexin isoproteins in normal mammary
gland
In the normal mammary gland connexin proteins were
primarily localized to the cell membranes using immunofluores-
cence. We confirmed Cx43 expression along the myoepithelial cell
layer and between stromal and endothelial cells (Fig. 3a), and
Cx26 expression between the luminal epithelial cells (Fig. 3b). In
addition, we detected, for the first time, Cx32 protein between the
luminal epithelial cells (Fig. 3c), Cx30 in the myoepithelial cells
and some in the luminal cells concentrating at their apex (Fig. 3d)
and Cx46 protein both in the myoepithelial and luminal epithelial
cells and in some stromal inflammatory cells (Fig. 3e). These
findings are summarized in a drawing in Fig. 3f.
Prognostic and clinicopathological correlates of connexin
expression in breast cancer
Connexin proteins were localized either at the cell membrane or
in the cytoplasm or both in breast carcinoma cells. Log-rank test
was used for revealing their prognostic associations and Spearman-
rank test (r) for their correlations with clinicopathological
variables. In line with mRNA data, there was a significant
statistical link between Cx30 expression (score 3+) and reduced
RFS in grade 3 patients (p = 0.016) (Fig. 4a–c) and a strong trend
concerning the whole patient cohort (p = 0.052) (Fig. 4 g). High
Cx30 levels (score 3+) also demonstrated a positive correlation
with mitotic index (MI) (r= 0.29). Likewise, confirming mRNA
data, Cx43 expression (scores 1–3+) was associated with signifi-
cantly longer RFS in the whole patient cohort (p = 0.026)
(Fig. 4d–f) and in grade 2 tumors (p = 0.032); and it correlated
positively with HR levels (r=0.23) and negatively with tumor
grade (r=20.22). Cx46 expression displayed a negative correla-
tion with tumor grade (r=20.2) but only a non-significant
positive trend with disease prognosis.
Discordant prognostic results were found between mRNA and
protein levels concerning the Cx26 and Cx32 isotypes. High Cx26
levels (score 3+) correlated with significantly improved RFS in the
whole patient cohort (p = 0.013) (Fig. 4 h), in the ER positive
(p = 0.007) and in Luminal A (p = 0.017) tumors (Fig. 4a–c). Also,
there was a negative correlation between Cx26 expression and
NPI (r=20.25). Medium to high Cx32 levels (scores 2–3+)
showed a significant negative correlation with RFS in the whole
cohort (p = 0.033) (Fig. 4i) and in Lumina B-Her2 positive tumors
(p = 0.025); and correlated positively with tumor grade (r= 0.34),
the presence of necrosis (r=0.19), NPI (r=0.28), mitotic index
(r=0.27) and Ki67 expression (r=0.21) and negatively with
hormone receptor levels (r=20.3).
Connexins in Breast Cancer Prognosis
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Prognostic power of connexins in relation to current
prognostic factors
Traditionally tested factors such as NPI value of.4, MI of .25
and Ki67 expression in .50% tumor cells (score 7 in our
evaluation) were statistically linked with worse RFS (pNPI = 0.011,
pMI=0.002, pKi67 = 0.001), while hormone receptor positivity was
linked to longer RFS (p = 0.002).
Results of Cox multivariate analysis in relation to RFS are
summarized in Table 3. Cx26, Cx30 and Cx43 expression could
be examined against necrosis, vascular invasion, MI, Ki67 index
and HR status, and Cx32 against vascular invasion. In breast
cancers, .50% Cx26 positive tumor cells (score 3) or .5% Cx43
positive tumor cells (scores 1–3) proved to be significantly stronger
independent prognostic factors, than vascular invasion or necrosis.
Furthermore, score 3 Cx26 positivity in tumor cells was found
nearly as a strong prognostic factor as HR or Ki67 index.
Expression of Cx43 in .50% of tumor cells (score 3) was also
confirmed nearly as a strong prognostic factor as MI. Score 3+ (.
50%) Cx30 positivity in grade 3 tumors proved to be a stronger
independent negative prognostic factor than MI or necrosis.
Furthermore, Cx32 positivity in ,20% Cx32 positive tumor cells
(scores 0–1) was confirmed to be a stronger prognostic factor than
vascular invasion.
Discussion
Despite testing for traditional and molecular prognostic and
predictive markers, the heterogeneity and therapy resistance urges
for further molecular stratification of breast cancers [37,38].
Deregulation of connexins and their cell membrane channels has
been implicated in breast carcinogenesis and tumor progression,
however, prognostic correlations of connexins have been rarely
found [9,39]. In this study, recent advances in probe specificity
Figure 1. Kaplan-Meier plots of significant prognostic correlations of elevated (.median) Cx43 (a-d and g–i) and Cx46 (e–f) mRNA
expression in 1809 breast cancers based on in silico analysis of Affymetrix array data. Cx43 expression was associated with improved
relapse/disease free survival (RFS) in a tumor group similar to SEER prevalence (a), in ER and lymph node positive tumors (b) and in ER positive
endocrine treated tumors (c), but reduced RFS in ER negative tumors (d). Elevated Cx46 levels were predictive for better RFS in the whole patient
cohort (e) and in ER and lymph node positive grade 3 patients (f). Elevated Cx43 mRNA levels were also correlated with significantly better distant
metastasis-free survival (DMFS) in ER positive endocrine treated patients (g) and in grade 2 cancers (h). Cx43 expression in ER negative patients was
linked with reduced overall survival (OS) (i). Significance (at p,0.05) was calculated using the log-rank test. HR: hazard ratio (at 95% Confidence
Interval).
doi:10.1371/journal.pone.0112541.g001
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and detection sensitivity allowed the correlation of connexin
mRNA and protein levels with breast cancer prognosis at unique
quality. We disclosed the expression of five connexin isotypes by
confirming the production of GJA1/Cx43, GJA3/Cx46 and
GJB2/Cx26 [27,31,40–42] and detecting, for the first time,
GJA6/Cx30 and GJB1/Cx32 both in the human pre-menopausal
mammary gland and breast carcinomas. Transcriptomic analysis
of both array datasets, Affymetrix and Illumina of ,2000 patients
each, cross-validated each other’s results. In line with the
correlations found at mRNA level, elevated Cx43 protein levels
were linked with significantly improved breast cancer outcome,
offering Cx43 protein detection as an independent prognostic
marker outperforming vascular invasion or necrosis. As a contrary,
elevated Cx30 mRNA and protein levels were associated with a
reduced disease outcome offering Cx30 protein detection as an
independent prognostic marker outperforming MI or necrosis.
The prognostic value of the rest of connexin isotypes revealed at
mRNA level was either lost (Cx46) or was discordant (Cx26 and
Cx32) with that observed at protein level suggesting a complex
regulation of these isotypes involving significant post-transcip-
tional/2translational control for further clarification. These data
show that differential connexin expression may serve as a potential
marker of breast cancer prognosis.
Table 2. Significant prognostic correlations of connexin mRNA expression data resulting from the in silico analysis of 1809
(Affymetrix) and 1988 (Illumina) breast cancers.
Connexin isotype Significant prognostic correlations Hazard ratio 95% Confidence Log-rank P
Positive Negative interval (significance)
GJA1 (Cx43) All patients (I) 0.67 0.57–0.79 2.5e-06
All patients (A/M) 0.63 0.47–0.85 0.002
SEER prevalence (A) 0.68 0.51–0.92 0.011
ER positive (A) 0.79 0.63–0.99 0.036
ER positive (I) 0.68 0.56–0.83 9.3e-05
Luminal A (I) 0.70 0.52–0.93 0.015
G2 tumors (A/M) 0.47 0.31–0.72 0.00038
ER & LN positive (A) 0.63 0.41–0.98 0.039
Endocrine treated (A) 0.46 0.29–0.73 0.00077
Endocrine treated (A/M) 0.31 0.14–0.66 0.0013
Endocrine treated (I) 0.63 0.49–0.84 0.0004
ER negative (A) 1.5 1.00–2.20 0.028
ER & LN negative (A/OS) 5.0 1.40–17.6 0.0052
ER negative (I) 1.31 0.96–1.18 0.09 (trend)
GJA3 (Cx46) All patients (A) 0.67 0.58–0.79 5,00E-07
All patients (I) 0.83 0.70–0.97 0.021
Luminal A (I) 0.72 0.53–0.98 0.036
ER negative (I) 0.74 0.55–0.99 0.045
HER2 positive (I) 0.66 0.45–0.95 0.026
Chemotherapy (I) 0.73 0.55–0.98 0.035
GJB1 (Cx32) All patients (A) 0.63 0.54–0.73 2.4e-09
All patients (I) 0.81 0.70–0.95 0.0095
ER positive (I) 0.82 0.68–0.99 0.043
Luminal B (I) 0.77 0.60–0.98 0.034
Endocrine treated (I) 0.81 0.66–1.00 0.046
GJB2 (CX26) Luminal B (I) 1.40 1.10–1.80 0.012
All patients (I) 1.20 1.00–1.40 0.058 (trend)
GJB6 (Cx30) All patients (I) 1.20 1.10–1.50 0.0088
ER positive (I) 1.40 1.10–1.70 0.0012
Luminal A (I) 1.50 1.10–2.10 0.0088
Luminal B (I) 1.50 1.10–1.90 0.0058
Endocrine treated 1.40 1.20–1.80 0.00082
HER2 positive 0.73 0.50–1.06 0.1 (trend)
Triple negative 0.72 0.49–1.05 0.085 (trend)
A: Affymetrix platform using relapse-free survival (RFS) data if not indicated, distant metastasis-free survival (DMFS) data indicated as M or overall survival data (OS).
I: Illumina platform using OS data only (not indicated).
doi:10.1371/journal.pone.0112541.t002
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Most data on the regulation of connexin expression are related
to Cx43 [43], which had good prognostic correlations between
mRNA and protein levels in this study. The tested gene array data
suggest that in ER positive primary breast cancers Cx43 mRNA
expression can be linked with tumor suppression [44], while in ER
negative cases with tumor protection [33]. 17b estradiol through
ERa can promote both the proliferation of mammary epithelial
cells [45] and the expression and functions of Cx43 channels,
which are implicated in cell cycle control [46,47]. The potential
control of tumor growth by Cx43 is likely to contribute to the
better differentiation and improved patient survival of ER positive
tumors [48]. In ER negative breast cancers other pathways
dominate in Cx43 expression potentially involving Wnt-1 and/or
Ras-Raf-MAPK activation [43], which can also be part of
mitogenic signaling responsible for the less differentiated pheno-
type and worse prognosis [49]. In these advanced tumors,
connexins can also contribute to metastatic invasion, transen-
dothelial diapedesis and colonization of breast cancer cells in line
with the observations made by several studies [19,32,33,50,51].
ER subtypes may also influence disease outcome [52] since
activating ERb may suppress both Cx43 expression and tumor
growth [46]; so as posttranslational regulation since Cx43 protein
levels were not linked to a prognostic inversion seen at mRNA
level in ER negative cases. The prognostic value of Cx43 was
preserved after hormone therapy, implying that Tamoxifen or
aromatase inhibitors can block mitogenic signaling [49] without
significantly reducing Cx43 expression and functions.
Elevated Cx30 transcript levels showed almost complete inverse
prognostic correlations compared to those of Cx43 with a reduced
survival in ER positive tumors and a strong trend for better
outcome in HER2 and triple negative cancers, consistent with a
complementary regulation of these connexins in breast carcino-
Figure 2. Kaplan-Meier plots of significant correlations between overall survival (OS) and elevated (.median) Cx30 (a–c), Cx43 (d–f)
and Cx46 (g–i) mRNA expression in 1988 breast cancers based on in silico analysis of Illumina array data. Elevated Cx30 levels were
linked with reduced OS in patients with luminal B tumors (a) and in ER positive endocrine therapy treated patients (b), but with a strong tendency for
improved OS in ER negative cases (c). Cx43 expression was associated with better OS in the whole cohort (d) and in ER positive endocrine treated
patients (e) but showed a strong trend for reduced OS in ER negative patients (f). Cx46 expression was associated with improved OS in the whole
cohort (g), in ER negative patients (h) and in HER2 positive patients (i). Significance (at p,0.05) was calculated using the log-rank test. HR: hazard ratio
(at 95% Confidence Interval).
doi:10.1371/journal.pone.0112541.g002
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genesis and progression. Cx46 mRNA expression was also linked
with improved survival in ER positive patients which, however,
was preserved also in ER negative patients, suggesting a reciprocal
regulation of Cx46 compared to Cx43 expression in this subgroup.
This is in line with data gained in lens cell cultures showing the
simultaneous down-regulation of Cx43 and upregulation of Cx46
expression by the tumor promoter phorbol ester (12-O-tetra-
decanoylphorbol-13-acetate) [53] or by the activation of the
MAPK/ERK pathway [54]. Differential regulation of connexin
isotypes are rather common and allows connexins to serve either
as conditional tumor suppressors in primary cancer or tumor
supporters in advanced, metastatic cases [30,32,33,51]. Examples
in gynecological tumors include the re-expression of Cx26 induced
by phorbol ester and its down-regulation via PR, which induce the
opposite effects on Cx43 [40,55,56]. Also, 17b estradiol promotes
Cx43 expression and function [46] but reduces Cx26 and Cx32
production and activities [57].
The cytoplasmic connexin protein we detected in breast cancers
can be compatible with the potential channel independent
functions of connexins observed in malignant tumors [14,50].
Tight correlations were found between mRNA and protein
expression and relatively coherent links between these and breast
cancer prognosis for connexin subtypes which were either
localized to the myoepithelial layer only (Cx43) or both to
myoepithelial and luminal epithelial cells (Cx46 and Cx30) in
normal mammary glands, as opposed to the luminal epithelia
related Cx26 and Cx32, which showed partly discordant
prognostic links. This suggests that connexin expression in
myoepithelia is more consistently regulated than in luminal cells
at least in a malignant tumor setting. Accordingly, in line with
mRNA data, elevated Cx43 and Cx30 protein levels were linked
with better and poorer RFS, respectively, in the whole patient
cohort. Most significantly, differential connexin expression allowed
the prognostic stratification of grade 2 patients into good or poor
RFS subgroups by is situ testing of Cx43 levels; or grade 3 patients
into poor or good OS subgroups by monitoring Cx30 levels.
Potential prognostic relevance of connexins was indirectly
supported by the positive statistical link of Cx43 protein levels
with ER positivity and its negative link with tumor grade and by
the positive link between Cx30 protein levels and mitotic index. As
Figure 3. Detection of connexin protein isotypes (Alexa-564, red) and the proliferation marker Ki67 protein (Alexa-518, green) in
normal pre-menopausal breast tissue. Punctuate Cx43 reaction was localized to the myoepithelial cell layer of normal mammary glands and to
adjacent stromal cells (arrow) (a). Both Cx32 (b and c) and Cx26 (d) proteins were found dominantly in the luminal epithelial cells. Cx46 protein was
found both in the myoepithelial and luminal cells and less in stromal inflammatory cells (arrow) (e and f). High power views show Cx32 mainly linked
to the luminal cells (c) and Cx46 mainly localized to the basal cells (f) involving both their cytoplasm and intercellular borders. Cx30 was revealed
along myoepithelial cells and at the apex of luminal epithelium and less in the rest of luminal cells, and along vascular endothelial cells (arrow) (g).
Co-localization of Cx26 (red) and Cx30 (green) in epithelial cells (yellow), involving the intercellular borders (h). Double immunofluorescence, cell
nuclei are stained blue using Hoescht. Summary drawing of our results shows potential homo- or heterocellular/typic interactions of Cx26 (red), Cx32
(blue), Cx46 (violet), Cx43 (green) and Cx30 (yellow) gap junctions in a normal mammary gland (i).
doi:10.1371/journal.pone.0112541.g003
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a contrary, Cx26 linked with worse outcome in luminal B patients
at the transcript level, was associated with better RFS in the whole
cohort and in ER positive patents at the protein level. Also, though
Cx32 expression was linked with improved RFS at the transcript
level, it showed an inverse prognostic link at the protein level in
most breast cancer subgroups.
Because of the close correlations between the results of
independent mRNA array platforms and the validated specificity
of the connexin antibodies used by western blots, the discordant
prognostic links between mRNA and protein levels may not be
associated with defective probes or techniques. Besides transcrip-
tion factors and epigenetic processes, post-transcriptional path-
ways can also be involved in the regulation of connexins in breast
cancer, which may more significantly affect Cx26 and Cx32 than
other isotypes [58]. These include micro-RNAs, since there are
multiple micro-RNA binding sites in the 39-untranslated regions of
connexin genes for cell-type-specific regulation of connexin
protein levels [59]. Tumor stage dependent differential degrada-
tion including lysosomal, autophagy mediated or proteasomal
mechanisms, such as described by the interaction of Cx43 and
TRIM21 an E3 ubiquitin-protein ligase, can modify connexin
levels [60,61], which need further clarification in tumor develop-
ment and progression. Furthermore, these and further posttrans-
lational modifications including phosphorylation, SUMOylation,
nitrosylation, hydroxylation, acetylation or methylation of con-
nexins, may alter protein conformation, which can diversely affect
recognition of antigenic epitopes by the antibodies we used
[62,63]. We previously showed that reduced Cx26 protein levels
were linked with improved prognosis after neoadjuvant chemo-
therapy where Cx32 protein detection had no prognostic impact
[7]. Other studies came to the opposite conclusion by linking the
loss of Cx26 expression to reduced survival in primary gastric and
colorectal carcinomas [64,65]. Therefore, Cx26 and Cx32 may
not be stable markers and their prognostic relevance in cancer
should be interpreted with particular care by considering tumor
type, stage and treatment.
The cell membrane association of connexins, we detected in the
normal mammary glands, is compatible with functioning channels,
which can be formed only between connexins of the same
subfamilies, either within GJA or GJB classes (see Fig. 3) [66].
Figure 4. Detection of connexin isoproteins in invasive breast cancers (b, c, e and f) and their significant correlations with relapse/
disease free survival (RFS) shown in Kaplan-Meier plots (a, d and g–i). Elevated Cx30 expression (score 3+) was linked with reduced RFS in
grade 3 patients (a–c) and with a strong positive trend in the whole cohort (g). Strong cell membrane and less cytoplasmic Cx43 staining (Alexa 564,
red) in b (3+) compared to c (1+) in highly proliferating (Ki67– Alexa 518, green) grade3 tumors. Cx43 expression (scores 1–3+) was associated with
improved RFS in the whole cohort (d–f). Strong cytoplasmic and less cell membrane Cx43 staining (red) in a tumor with low proliferation rate (green
nuclei) (e) and stromal Cx43 signal only in a highly proliferating tumor (f ). Unlike at mRNA level, elevated Cx26 signal (score 3+) correlated with
improved RFS (h), while medium to high Cx32 levels (scores 2–3+) showed a negative link with RFS in the whole patient cohort (i). Significance (at p,
0.05) was calculated using the log-rank test. Double immunofluorescence, cell nuclei are labeled blue using Hoescht.
doi:10.1371/journal.pone.0112541.g004
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Based on our findings, compatible connexins detected in the cell
borders, which likely involve the cell membranes, can potentially
form heterocellular channels in the normal mammary gland to be
further clarified. Theoretically, myoepithelial Cx43 (GJA1) can
form heterocellular channels with Cx46 (GJA6) but not with Cx30
(GJB6) of the myo- and luminal epithelium. Cx26 (GJB2) and
Cx32 (GJB3) can also form homo- and heterotypic/heretomeric
channels between luminal cells [67] and heterocellular channels
with the myoepithelial Cx30 [68,69]. This complexity and the
differential regulation of connexins offer a substantial plasticity for
the fine regulation mammary gland functions including cyclic
proliferation, regression and lactation, through connexin channels
[28].
In conclusion, the selective expression and compatibility of the
five connexin isotypes revealed in human mammary epithelial
layers allow complex regulation of glandular functions through
direct cell-cell communication. In breast cancer, the differential
expression of connexins either at mRNA and protein level may be
used for the potential prognostic stratication of tumor subtypes. In
particular, Cx43 and Cx30, which respectively show positive and
negative prognostic values concordant between mRNA and
protein levels, offer themselves as potential markers of breast
cancer outcome.
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